The Path Forward in MF: Small Molecules in the Limelight
Cancers · 25.04.2026 · 18 (9) · 1370
DOI: 10.3390/cancers18091370 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.04.2026. Verfasst von Elisabetta Abruzzese und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, St. Eugenio Hospital, Tor Vergata University, ASL Roma2, 00144 Rome, Italy. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, extramedullary hematopoiesis (particularly symptomatic splenomegaly), constitutional symptoms, progressive cytopenias, and, in a subset of patients, leukemic transformation. The advent of the JAK1/2 inhibitor ruxolitinib has revolutionized the management of MF, substantially improving splenomegaly, symptom burden, and, in some settings, overall survival. However, a substantial percentage of patients fail to achieve sustained benefit, are intolerant, or become refractory; real-world and clinical trial data indicate that approximately half of treated patients discontinue ruxolitinib treatment within 3 years and up to approximately 75% within 5 years, with poor outcomes after discontinuation (median survival in several series is approximately 12–14 months). In recent years, several new small molecules that act beyond the JAK-STAT axis have emerged in clinical development. These include agents targeting telomerase (imetelstat), epigenetic regulation via BET inhibition (pelabresib/CPI-0610), the MDM2-p53 axis (navtemadlin/KRT-232), erythroid maturation and the bone marrow microenvironment (luspatercept), PI3K signaling (parsaclisib), and PIM inhibitors (nuvisertib). Early clinical data show promising results for symptom and splenic control in specific settings and, importantly, suggest potential disease-modifying activity (improvements in marrow fibrosis and molecular responses) for some compounds. This review summarizes the biological rationale, key clinical data (efficacy and safety), ongoing randomized trials, and remaining knowledge gaps for these non-JAK small molecules in MF and offers practical considerations for integrating them into contemporary treatment algorithms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology, St. Eugenio Hospital, Tor Vergata University, ASL Roma2, 00144 Rome, Italy.
- Bone Marrow Transplant Unit, ASST Spedali Civili, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.
- Pharmacy, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy.
ORCID-Profile: Elisabetta Abruzzese, Malgorzata Monika Trawinska, Simona Bernardi, Martina Canichella
Zitieren
APA
Abruzzese, E., Trawinska, M. M., Bernardi, S., Checcoli, A., & Canichella, M. (2026). The Path Forward in MF: Small Molecules in the Limelight. Cancers, 18(9), 1370. https://doi.org/10.3390/cancers18091370
Vancouver
Abruzzese E, Trawinska MM, Bernardi S, Checcoli A, Canichella M. The Path Forward in MF: Small Molecules in the Limelight. Cancers. 2026;18(9):1370. doi:10.3390/cancers18091370
BibTeX
@article{Abruzzese2026,
author = {Abruzzese, Elisabetta and Trawinska, Malgorzata Monika and Bernardi, Simona and Checcoli, Alessandra and Canichella, Martina},
title = {The Path Forward in MF: Small Molecules in the Limelight},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1370},
doi = {10.3390/cancers18091370}
}
EUVIMED